Table 3.
Sensitivity and specificity of Sj23-LHD-, SjSAP4-, SjSAP5-, SjSAP4 + Sj23-LHD- and SjSAP5 + Sj23-LHD-ELISA tested against 180 serum samples from the first SjP patient cohort.
| Serum dilution | Antigens | Sensitivity (KK-positive n = 67) | Sensitivity (KK-negative n = 113) | Specificity |
|---|---|---|---|---|
| 1:100 | Sj23-LHD | 61.19% | 22.12% | 93.33% |
| SjSAP4 | 92.54% | 75.22% | 91.67% | |
| SjSAP5 | 91.04% | 66.37% | 95.00% | |
| SjSAP4 + Sj23-LHD | 92.54% | 76.99% | 91.67% | |
| SjSAP5 + Sj23-LHD | 91.04% | 68.14% | 93.33% | |
| 1:250 | Sj23-LHD | 53.73% | 21.24% | 95.00% |
| SjSAP4 | 94.03% | 72.57% | 98.33% | |
| SjSAP5 | 85.07% | 61.95% | 96.67% | |
| SjSAP4 + Sj23-LHD | 91.04% | 67.26% | 96.67% | |
| SjSAP5 + Sj23-LHD | 89.55% | 65.49% | 96.67% | |
| 1:500 | Sj23-LHD | 46.27% | 16.81% | 96.67% |
| SjSAP4 | 86.57% | 50.44% | 96.67% | |
| SjSAP5 | 76.12% | 45.13% | 98.33% | |
| SjSAP4 + Sj23-LHD | 88.06% | 53.10% | 98.33% | |
| SjSAP5 + Sj23-LHD | 79.10% | 46.90% | 96.67% | |
| 1:1000 | Sj23-LHD | 19.40% | 10.62% | 98.33% |
| SjSAP4 | 83.58% | 38.05% | 98.33% | |
| SjSAP5 | 74.63% | 33.63% | 98.33% | |
| SjSAP4 + Sj23-LHD | 82.09% | 39.82% | 95.00% | |
| SjSAP5 + Sj23-LHD | 73.13% | 37.17% | 98.33% |